Actualités Medexus Pharmaceuticals Inc - MDP | Actions TSX Venture Exchange

Complete Response Letter Received from FDA for Treosulfan

TORONTO and CHICAGO and WEDEL, Germany, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc...

Medexus Appoints New Chief Financial Officer

TORONTO and CHICAGO, July 19, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the...

Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in C...

TORONTO and CHICAGO and WEDEL, Germany, July 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada

TORONTO and CHICAGO, June 28, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021

Transformative licensing agreement for treosulfan in the U.S. completed February 2, 2021 Cash and cash...

Medexus Announces Graduation to the Toronto Stock Exchange

TORONTO and CHICAGO and MONTREAL, June 15, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus”...

Medexus to Present at Raymond James Human Health Innovation Conference

TORONTO, CHICAGO and MONTREAL, June 14, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Schedules Fiscal Year 2021 Conference Call

TORONTO and CHICAGO and MONTREAL, June 11, 2021 (GLOBE NEWSWIRE) -- , June 11, 2021 - Medexus Pharmaceuticals...

Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch

TORONTO, CHICAGO and MONTREAL, June 10, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States

TORONTO and CHICAGO and MONTREAL, June 09, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus to Present at The LD Micro Virtual Invitational XI on June 8th

TORONTO and CHICAGO and MONTREAL, June 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Announces Amendments to its Credit Agreements

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO and...

Medexus to Present at the Sidoti & Company Virtual Microcap Conference on May 19th

TORONTO, CHICAGO and MONTREAL, May 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Medexus Announces Conference Participation for April 2021

TORONTO and CHICAGO and MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the...

Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees

TORONTO, CHICAGO and MONTREAL, March 31, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company”...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medexus Pharmaceuticals Inc (MDP)

Votre Hub pour des idées et discussions en direct en temps réel

MDP Actualités

Complete Response Letter Received from FDA for Treosulfan

Medexus Appoints New Chief Financial Officer

Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in C...

Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada

Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021

Medexus Announces Graduation to the Toronto Stock Exchange

Medexus to Present at Raymond James Human Health Innovation Conference

Medexus Schedules Fiscal Year 2021 Conference Call

Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States

Medexus to Present at The LD Micro Virtual Invitational XI on June 8th

Medexus Announces Amendments to its Credit Agreements

Medexus to Present at the Sidoti & Company Virtual Microcap Conference on May 19th

Medexus Announces Conference Participation for April 2021

Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Medexus Pharmaceuticals Inc (MDP) Actualités

Medexus Pharmaceuticals Inc (MDP)

Votre Hub pour des idées et discussions en direct en temps réel

MDP Actualités

Complete Response Letter Received from FDA for Treosulfan

Medexus Appoints New Chief Financial Officer

Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, Treosulfan, in C...

Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada

Medexus Revenue Increases 43.5% to a Record US$79.7 Million for Fiscal 2021

Medexus Announces Graduation to the Toronto Stock Exchange

Medexus to Present at Raymond James Human Health Innovation Conference

Medexus Schedules Fiscal Year 2021 Conference Call

Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch

Medexus Announces Availability of Triamcinolone Hexacetonide in the United States

Medexus to Present at The LD Micro Virtual Invitational XI on June 8th

Medexus Announces Amendments to its Credit Agreements

Medexus to Present at the Sidoti & Company Virtual Microcap Conference on May 19th

Medexus Announces Conference Participation for April 2021

Medexus Reports All Medexus Non-Executive Directors Choose RSUs in Lieu of Cash Fees

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités